Hawaii Biotech
Hawaii Biotech, Inc, a biotechnology company, focuses on the research and development of prophylactic vaccines for infectious diseases
About Hawaii Biotech
Hawaii Biotech, accessible via hibiotech.com, is a pioneering company in the biotechnology sector, focusing on the development of medical countermeasures against infectious diseases. The company specializes in creating drugs for the treatment of Anthrax intoxication and botulism in humans. These conditions are caused by exposure to Anthrax spores and BoNT type A toxins, respectively.
Hawaii Biotech operates in the pharmaceutical and biotechnology market, primarily serving government agencies, healthcare providers, and organizations involved in public health and safety. The company’s business model revolves around its proprietary vaccine platform, which includes multiple recombinant protein subunit vaccine candidates. These vaccines are developed using a unique protein production platform that ensures high-quality proteins capable of eliciting strong immune responses, often superior to traditional live or inactivated virus methods.
Revenue generation for Hawaii Biotech comes from multiple streams, including government contracts, grants, and partnerships with pharmaceutical companies. By focusing on high-demand areas such as biodefense and public health, the company positions itself as a crucial player in the development of vaccines and treatments for serious infectious diseases.
In summary, Hawaii Biotech is dedicated to advancing public health through innovative biotechnology solutions, particularly in the realm of infectious disease countermeasures.
Source: Dealroom company dataNews
Open roles
Hawaii Biotech in the Honolulu ecosystem
The Hawaii Biotech office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
- HMHMS Hawaii Management
Series B and later1 investor entered at this stage
Advantage Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Hawaii Biotech on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Hawaii Biotech on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

